Published in J Clin Oncol on January 21, 2009
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment. Ann Surg Oncol (2011) 1.24
Recent advances in the management of adenocarcinoma of the small intestine. Gastrointest Cancer Res (2009) 1.14
Small bowel adenocarcinoma of the jejunum: a case report and literature review. World J Surg Oncol (2016) 1.10
Small intestinal cancer: a population-based study of incidence and survival patterns in the United States, 1992 to 2006. Cancer Epidemiol Biomarkers Prev (2010) 1.00
Small bowel adenocarcinomas--existing evidence and evolving paradigms. Nat Rev Clin Oncol (2013) 0.99
Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol (2009) 0.97
A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol (2011) 0.97
Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One (2013) 0.94
Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist (2012) 0.92
Primary squamous cell carcinoma of the ampulla of Vater: a case report. Surg Case Rep (2016) 0.89
Management of adenocarcinoma of the small intestine. Gastrointest Cancer Res (2009) 0.85
A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol (2013) 0.84
Tumors of ampulla of Vater: A case series and review of chemotherapy options. World J Gastrointest Oncol (2012) 0.84
Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. BMC Cancer (2011) 0.82
Duodenal adenocarcinoma: Advances in diagnosis and surgical management. World J Gastrointest Surg (2016) 0.82
Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. J Cancer Res Clin Oncol (2009) 0.80
S-1 treatment leading to complete remission of advanced duodenal adenocarcinoma: A case report. Mol Clin Oncol (2015) 0.80
Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience. BMC Cancer (2015) 0.80
Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman. Diagn Pathol (2013) 0.80
The effects of chemotherapy on primary small bowel cancer: A retrospective multicenter observational study in Japan. Mol Clin Oncol (2013) 0.79
Successful treatment of recurrent small bowel adenocarcinoma by cytoreductive surgery and chemotherapy: a case report and review of the literature. J Med Case Rep (2010) 0.78
Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book (2014) 0.77
Impact of Standardized Allergen-Removed Rhus verniciflua Stokes Extract on Advanced Adenocarcinoma of the Ampulla of Vater: A Case Series. Evid Based Complement Alternat Med (2013) 0.76
Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature. World J Gastrointest Oncol (2016) 0.75
Small Bowel Adenocarcinoma as the Cause of Gastrointestinal Bleeding in Celiac Disease: A Rare Malignancy in a Common Disease. Case Rep Oncol Med (2015) 0.75
Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6. J Gastrointest Oncol (2014) 0.75
A Patient With Metastatic Adenocarcinoma of the Jejunum Who Had a Prolonged Complete Response to FOLFOX. Gastrointest Cancer Res (2012) 0.75
Prognostic Factors and Clinical Characteristics of Patients with Primary Duodenal Adenocarcinoma: A Single-Center Experience from China. Biomed Res Int (2016) 0.75
Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma. Oncol Lett (2010) 0.75
Establishing a standard of care for small bowel adenocarcinomas: challenges and lessons learned. Oncologist (2012) 0.75
Pancreatic cancer: Is it time for Dr Whipple's orphans to have a Facebook page? Nat Rev Clin Oncol (2012) 0.75
Widespread lymph node recurrence of major duodenal papilla cancer following pancreaticoduodenectomy. World J Gastroenterol (2015) 0.75
Most small bowel cancers are revealed by a complication. Einstein (Sao Paulo) (2015) 0.75
Small bowel adenocarcinoma arising in a patient with hereditary hemorrhagic telangiectasia: A case report. Oncol Lett (2016) 0.75
A Retrospective Review of Chemotherapy for Patients with Small Bowel Adenocarcinoma in British Columbia. J Cancer (2016) 0.75
Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine. Intern Med (2017) 0.75
A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. Int J Clin Oncol (2017) 0.75
Clinical use of molecular targeted agents for primary small bowel adenocarcinoma: A multicenter retrospective cohort study by the Osaka Gut Forum. Oncol Lett (2017) 0.75
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA (1995) 11.90
Pancreatic cancer. Lancet (2004) 11.63
A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry (1996) 7.80
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol (2009) 5.42
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg (2005) 4.86
Differences in the use of psychiatric outpatient services between the United States and Ontario. N Engl J Med (1997) 4.78
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology (2009) 4.72
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol (2008) 4.68
Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics (2004) 4.58
Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry (1999) 4.57
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol (2006) 4.50
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol (2008) 4.37
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 4.34
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19
Metastatic patterns in adenocarcinoma. Cancer (2006) 4.16
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg (2007) 4.09
Childhood abuse and lifetime psychopathology in a community sample. Am J Psychiatry (2001) 4.07
Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA (2009) 3.86
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol (2008) 3.85
Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology (2002) 3.59
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg (2008) 3.36
Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst (2005) 3.31
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol (2004) 3.10
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Differential expression in SAGE: accounting for normal between-library variation. Bioinformatics (2003) 3.06
Adequacy and duration of antidepressant treatment in primary care. Med Care (1992) 3.04
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther (2008) 2.99
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Rethinking practitioner roles in chronic illness: the specialist, primary care physician, and the practice nurse. Gen Hosp Psychiatry (2001) 2.82
Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics (2005) 2.81
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene (2003) 2.79
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol (2008) 2.78
Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res (2005) 2.76
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol (2009) 2.69
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer (2011) 2.68
Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg (2004) 2.62
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol (2006) 2.61
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res (2013) 2.57
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol (2009) 2.52
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol (2009) 2.52
Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol (2008) 2.52
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One (2011) 2.49
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer (2005) 2.49
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol (2012) 2.43
Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol (2007) 2.40
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer (2007) 2.40
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene (2004) 2.35
The Drosophila RAD21 cohesin persists at the centromere region in mitosis. Curr Biol (2000) 2.29
High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol (2011) 2.28
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res (2003) 2.27
Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol (2009) 2.27
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol (2009) 2.23
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol (2011) 2.23
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res (2003) 2.23
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res (2011) 2.22
Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol (2012) 2.22
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res (2005) 2.22
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
One-year prevalence of psychiatric disorder in Ontarians 15 to 64 years of age. Can J Psychiatry (1996) 2.18